Stock DNA
Pharmaceuticals & Biotechnology
SEK 208 Million (Micro Cap)
NA (Loss Making)
NA
0.00%
-0.16
-12.41%
0.35
Revenue and Profits:
Net Sales:
40 Million
(Quarterly Results - Jun 2025)
Net Profit:
-15 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-71.87%
0%
-71.87%
6 Months
-67.07%
0%
-67.07%
1 Year
-56.88%
0%
-56.88%
2 Years
-90.84%
0%
-90.84%
3 Years
-99.02%
0%
-99.02%
4 Years
-99.32%
0%
-99.32%
5 Years
-99.02%
0%
-99.02%
Xbrane Biopharma AB for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
191.39%
EBIT Growth (5y)
15.23%
EBIT to Interest (avg)
-67.28
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0.58
Sales to Capital Employed (avg)
0.43
Tax Ratio
8.45%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
1.69
EV to EBIT
-77.01
EV to EBITDA
37.51
EV to Capital Employed
1.66
EV to Sales
2.50
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-2.16%
ROE (Latest)
-24.41%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
Bullish
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bullish
Dow Theory
No Trend
No Trend
OBV
Mildly Bearish
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
Jun'25
Mar'25
Change(%)
Net Sales
39.90
93.20
-57.19%
Operating Profit (PBDIT) excl Other Income
-0.60
24.10
-102.49%
Interest
5.50
8.40
-34.52%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-15.50
19.20
-180.73%
Operating Profit Margin (Excl OI)
-118.60%
205.30%
-32.39%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2025 is -57.19% vs 41.64% in Mar 2025
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2025 is -180.73% vs 136.29% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
198.70
238.70
-16.76%
Operating Profit (PBDIT) excl Other Income
-148.30
-289.00
48.69%
Interest
36.00
18.60
93.55%
Exceptional Items
0.00
16.30
-100.00%
Consolidate Net Profit
-265.00
-322.00
17.70%
Operating Profit Margin (Excl OI)
-868.10%
-1,300.30%
43.22%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is -16.76% vs 314.41% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 17.70% vs -91.10% in Dec 2023
About Xbrane Biopharma AB 
Xbrane Biopharma AB
Pharmaceuticals & Biotechnology
Xbrane Biopharma AB, formerly Xbrane Bioscience AB, is a Sweden-based provider of biotechnology research and development services. It develops biogenerics for injectable slow release drugs and high-yield protein expression technology for the development of biosimilars. The Company's main products are Sperotide, a generic on the originator drug marketed under the trademarks Decapeptyl, Trelstar and Pamorelin, as well as Xlucane, a biosimilar on the originator drug sold under the trademark Lucentis.






